<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075266</url>
  </required_header>
  <id_info>
    <org_study_id>WA39085</org_study_id>
    <secondary_id>2016-002667-34</secondary_id>
    <nct_id>NCT04075266</nct_id>
  </id_info>
  <brief_title>A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-year study will evaluate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages &gt;/= 10 to &lt; 18
      years with relapsing-remitting multiple sclerosis (RRMS). The first 24-week period will serve
      to determine the dose of ocrelizumab to be further investigated in the subsequent Phase III
      study in children and adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">August 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 26, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentration of Ocrelizumab</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of CD19+ B-cell Count in Blood</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Adverse Events</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>Severity of adverse events is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Circulating White Blood Cells (WBC)</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>WBC include B cells, T cells, natural killer (NK) cells and other leukocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Milestones - Growth velocity: Height. Change in height measured in centimeters (cm)</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Milestones: Bone age assessment by wrist/hand radiographs</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>Bone age should be reported according to the Greulich and Pyle Atlas (Greulich and Pyle, 1959)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Milestones: Male and female puberty assessed by Tanner staging</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>Tanner stages (stages 1 to 5) (Tanner, 1986)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Developmental Milestones: Age at menarche, related with the female reproductive status</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>This milestone is recorded as date of menarche (day, month, year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Blood Immunoglobulins</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titers Against Standard Vaccines</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
    <description>Measurement of antibody titers to common antigens (mumps, rubella, varicella, S. pneumoniae)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs) to Ocrelizumab</measure>
    <time_frame>6 months, Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a body weight from &gt;/= 25 kg to &lt; 40 kg (with at least 2 participants with a body weight from &gt;/= 25 kg to &lt;/= 35 kg) will receive 300 milligram (mg) ocrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a body weight &gt;/= 40 kg (with at least 2 participants with a body weight &gt;/= 40 kg but &lt;/= 50 kg) will receive 600 mg ocrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from &gt;/= 25 kg to &lt; 40 kg may be enrolled and receive another dose level of ocrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight &gt;/= 40 kg may be enrolled and receive another dose level of ocrelizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.
Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3 (optional)</arm_group_label>
    <arm_group_label>Cohort 4 (optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt;/= 25 kg

          -  Children and adolescents must have received all childhood required vaccinations

          -  Female participants of childbearing potential must agree to either remain completely
             abstinent or to use reliable means of contraception

          -  Diagnosis of relapsing-remitting multiple sclerosis (RRMS)

          -  Expanded Disability Status Scale (EDSS) at screening: 0−5.5, inclusive

          -  Neurologic stability for &gt;/= 30 days prior to screening, and between screening and
             baseline

          -  Participants naive to prior disease-modifying therapy (DMT)

          -  Participants who have had at least 6 contiguous months of DMT within the past 1 year
             must have evidence of disease activity occurring after the full 6-month course of
             treatment, that is, at least one relapse or &gt;/= 1 Gd-enhancing lesion(s) on a
             T1-weighted brain MRI

        Exclusion Criteria:

          -  Known presence or suspicion of other neurologic disorders that may mimic MS,
             including, but not limited to, acute disseminated encephalomyelitis, neuromyelitis
             optica or neuromyelitis optica spectrum disorders and any neurologic, somatic, or
             metabolic condition that could interfere with brain function or normal cognitive or
             neurological development

          -  Patients that are aquaporin 4 positive and myelin oligodendrocyte glycoprotein (MOG)
             antibody positive are not eligible to participate in the study.

          -  In case of an ADEM-like appearance of the first MS attack, a second attack with clear
             MS-like features is required.

          -  Infection requiring hospitalization or treatment with IV anti-infective agents

          -  History or known presence of recurrent or chronic infection (e.g., HIV, syphilis,
             tuberculosis)

          -  Receipt of a live or live-attenuated vaccine within 6 weeks prior to treatment
             allocation

          -  History or laboratory evidence of coagulation disorders

          -  Peripheral venous access that precludes IV administration and venous blood sampling

          -  Inability to complete a magnetic resonance imaging (MRI) scan

          -  History of cancer, including solid tumors, hematologic malignancies, and carcinoma in
             situ

          -  History of a severe allergic or anaphylactic reaction to humanized or murine
             monoclonal antibody (mAbs) or known hypersensitivity to any component of ocrelizumab
             solution

          -  Previous treatment with B-cell−targeted therapies

          -  Percentage of CD4 &lt; 30%

          -  Absolute Neutrophil Count &lt; 1.5x1000/microliter

          -  Lymphocyte count below the lower limit of normal (LLN) for age- and sex-specific
             reference range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WA39085 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University health</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Childrens Hospital Rocky Mountain MS Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens National Health Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville Physicians</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Universtiy school of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akron Childrens Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù; Divisione di Neurologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea; UOC Neurologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs A.O.U.San Martino Ist; Dinogmi</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Antonio Abate; Neurologia 2 - Sclerosi Multipla e Recupero Neurologico</name>
      <address>
        <city>Gallarate</city>
        <state>Lombardia</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico V. Emanuele - P.O G. Rodolico; Clinica Neurologica, Centro Sclerosi Multipla</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Neurologii Rozwojowej</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H. Swiecickiego U.M. w Poznaniu; Od. Kliniczny Neurologii Dzieci i Młodziezy</name>
      <address>
        <city>Poznań</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik Centrum Zdrowia Dziecka; Klinika Neurologii i Epileptologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki; Klinika Neurologii</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

